상피성 장액성 난소 종양에서 Tissue inhibitors of metalloproteinase-2 (TIMP-2) 의 발현 양상 = The expression of tissue inhibitors of metalloproteinase -2 (TIMP-2) in epithelial serous ovarian tumors

다국어 초록 (Multilingual Abstract)

Objective: Tissue inhibitors of metalloproteinases (TIMPs) play a key role in maintaining homeostasis of the extracellular matrix (ECM) by controlling matrix metalloproteinases (MMPs). In addition to their role in regulating MMPs, TIMPs have also been shown to have pluripotential effects on cell growth, apoptosis and differentiation. The aim of this study was to examine TIMP-2 level in serous ovarian tumor tissues and to understand further the role of TIMP-2 protein in ovarian tumorigenesis.
Methods: Expression of TIMP-2 was assessed by immunohistochemistry in a total of 57 ovarian specimens including five normal ovaries, 12 benign serous cystadenomas, 20 serous borderline tumors and 20 serous carcinomas.
Results: The present study found that TIMP-2 immunostaining was significantly more frequent in serous carcinomas, mainly in tumor epithelium, compared with cells of the other tissues studied.
Conclusion: TIMP-2 in serous ovarian carcinoma may function to favor tumor growth in serous ovarian tumorigenesis. Additional research is now needed to elucidate further the role of TIMP-2 in the biological behavior of ovarian serous tumors.

국문 초록 (Abstract)

목적: Tissue inhibitors of metalloproteinases-2 (TIMP-2)는 matrix metalloproteinases (MMPs)를 조절함으로써 종양의 성장 및 진행을 저해하는데 중요한 역할을 한다고 알려져 왔으며, 최근에는 MMPs 조절 기능 외에, 세포의 성장, 사멸 및 분화 과정에서 다양한 역할을 한다고 보고되어왔다. 난소 종양에서는 TIMP-2에 관한 연구가 많지 않으며, 그 결과 또한 이견이 있는 상태로 조직 형태에 따라 TIMP-2의 발현 양상이 다를 수 있음이 보고되어 왔다. 따라서, 본 연구는 난소 종양 중 상피성 장액성 종양 조직에 국한하여 TIMP-2의 발현 양상을 조사하고, 그 기능을 고찰하고자 하였다.
방법: 정상 난소 5예, 양성 장액성 낭선종 12예, 경계성 장액성 낭선종 20예, 장액성 선암 20예를 포함한 총 57예의 난소 조직을 대상으로, 면역조직화학염색법으로 TIMP-2의 발현 양상을 조사하였고, 이 결과와 병리 양상과의 상관관계를 알아보았다.
결과: 장액성 선암에서의 TIMP-2의 발현 정도가 정상 난소, 양성 장액성 낭선종 및 경계성 장액성 낭선종과 비교하여 의미있게 높게 나타났으며 (P=0.02, P<0.001, P=0.025, 각각), 장액성 선암 환자들의 병기 및 조직 분화도와 TIMP-2의 발현 정도는 상관관계를 보이지 않았다 (p=0.788, p=0.441, 각각).
결론: TIMP-2는 장액성 선암 조직에서 정상 난소, 양성 장액성 낭선종 및 경계성 장액성 낭선종과 비교하여 높게 발현되었으며, 이러한 결과는 TIMP-2 가 장액성 선암 세포에서는 종양의 성장을 돕는 방향으로 작용할 가능성을 시사하며, 이에 대해서는 향후 새로운 연구가 필요하리라 사료된다.

참고문헌 (Reference)

1 "Treatment of colorectal liver metastases by adenoviral transfer of tisue inhibitor of metaloproteinases-2 into the liver tisue" 60 : 5723-5730, 2000

2 "Tisue inhibitors of metaloproteinases" 1477 : 267-283, 2000

3 "Tisue inhibitor of metaloproteinases-2 inhibits bFGF-induced hu-man microvascular endothelial cel proliferation" 351-8,

4 "Tisue inhibitor of metaloproteinases-2 (TIMP-2) suppreses TKR-growth factor signaling independent of metaloproteinase inhibition" 276 : 3203-3214, 2001

5 "Tisue inhibitor of metaloproteinases control of expression and biological functions" 329-41, pharmacolther1993;59

6 "Tissue inhibitor of metaloproteinase-2" 231-2 4, febslet1992;296

7 "The prognostic value of metal-loproteinases and angiogenic factors in ovarian carcinoma" 187 : 39-45, 2002

8 "TIMP-2 over-expression reduces invasion and angio-genesis and protects B16F10 melanoma cels from apoptosis" 75 : 246-253, 1998

9 "TIMP-2 mediated inhibition of angiogenesis" 114 : 171-180, 2003

10 "Sur-vin, bcl-2 and matrix metaloproteinase-2 enhance pro-gresion of clear cel- and serous-type ovarian carcinomas" 19 : 537-542, 2001

11 "Prognostic significance of stromal metaloproteinase-2 in ovarian adeno-carcinoma and its relation to carcinoma progresion" 92 : 559-567, 2004

12 "Positive corelation betwen inhibitors of matrix metaloproteinase 1 and matrix metaloproteinases in malignant ovarian tumor tissues" 120 : 109-115, 1997

13 "Ovarian carcinoma cels in serous effusions show altered MMP-2 and TIMP-2 mRNA levels" 37 : 2040-2049, 2001

14 "Metaloproteinase inhibi-tors" 115 : 3719-3727, 2002

15 "Matrix metaloproteinases in cancer" 99 : 157-166, 2002

16 "Matrix metaloproteinase expression is related to angiogenesis and histologic grade in spindle cel soft tissue neoplasms of the extremities" 123 : 405-414, 2005

17 "Matrix metalopro-teinase inhibitors and cancer" 295 : 2387-2392, 2002

18 "MP-2 and TIMP-2 expression corelates with poor prognosis in cervical carcinoma-a clinicopathologic study using imunohistochemistry and mRNA in situ hybridization" 73 : 372-382, 1999

19 "Increased expression of tissue inhibitor of metalloproteinase-2 in clear cell carcinoma of the ovary" 9 : 569-575, 2003

20 "Increased expresion of matrix metalopro-teinases (MP)-2, MMP-9, and the urokinase-type plasmi-nogen activator is associated with progression from benign to advanced ovarian cancer" 7 : 2396-2404, 2001

21 "How matrix metaloproteinases regu-late cel behavior" 17 : 463-516, 2001

22 "High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer" 56 : 1654-1659, 1996

23 "High levels of TIMP-2 corelate with adverse prognosis in breast cancer" 89 : 118-121, 2000

24 "High levels of MMP-2 MT1-MP and TIMP-2 mRNA corelate with poor survival in ovarian carcinoma" 17 : 799-808, 1999

25 "Expression of matrix metaloproteinase-26 and tissue inhibitors of metal-loproteinases TIMP-3 and -4 in benign endometrium and en-dometrial cancer" 89 : 453-459, 2003

26 "Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms" 78 : 106-112, 2000

27 "Expresion of matrix metaloproteinases and their inhibitors in medulloblastomas and their prognostic relevance" 10 : 4746-4753, 2004

28 "Expresion of matrix metalloproteinases (MP-2, MMP-9, MT1-MP) and their inhibitors (TIMP-1, TIMP-2) in comon epithelial tu-mors of the ovary" 17 : 673-681, 2000

29 "Expresion of latent matrix metaloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer" 82 : 291-298, 2001

30 "Complex roles of tisue inhibi-tors of metaloproteinases in cancer" 21 : 2245-2252, 2002

31 "Changes in matrix metaloproteinases and their endogenous inhibitors during tumor progresion in the uterine cervix" 129 : 123-131, 2003